These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2286 related items for PubMed ID: 9915665

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Insulin resistance syndrome and type 2 diabetes mellitus.
    Erkelens DW.
    Am J Cardiol; 2001 Oct 11; 88(7B):38J-42J. PubMed ID: 11595198
    [Abstract] [Full Text] [Related]

  • 7. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC.
    Pharmacotherapy; 1995 Oct 11; 15(3):317-37. PubMed ID: 7667166
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
    Rustemeijer C, Schouten JA, Voerman HJ, Hensgens HE, Donker AJ, Heine RJ.
    Diabetes Metab Res Rev; 2000 Oct 11; 16(2):82-7. PubMed ID: 10751747
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
    Bell DS.
    Clin Ther; 1995 Oct 11; 17(5):901-10. PubMed ID: 8595642
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
    Steiner G.
    Treat Endocrinol; 2005 Oct 11; 4(5):311-7. PubMed ID: 16185099
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes.
    Goldberg RB.
    Am J Manag Care; 2000 Aug 11; 6(13 Suppl):S682-91; discussion S692-6. PubMed ID: 11183421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 115.